Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP003208)
SBP Name
DARPin Ensovibep
Synonyms
MP0420
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase III
Protein Scaffold Information of This SBP
Scaffold ID PS027
Scaffold Info
[1] , [2]
Scaffold Name DARPin
Scaffold Class Non-Antibody
Fold Type Alpha-Helices + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Spike glycoprotein
BTS Info
Binder SARS-CoV-2 infection (COVID-19) [ICD-11: XN109] N.A. Molecular Partners; Novartis [1] , [2]
Clinical Trial Information of This SBP
NCT04501978 Click to show the Detail
Indication COVID-19
Phase Phase III
Title ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)
Status Recruiting
Sponsor .
NCT04828161 Click to show the Detail
Indication COVID-19
Phase Phase II; Phase III
Title A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 (EMPATHY)
Status Recruiting
Sponsor Molecular Partners AG
NCT04834856 Click to show the Detail
Indication COVID-19
Phase Phase II
Title Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients
Status Recruiting
Sponsor Molecular Partners AG
NCT04870164 Click to show the Detail
Indication COVID-19
Phase Phase I
Title Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
Status Recruiting
Sponsor Molecular Partners AG
NCT05780463 Click to show the Detail
Indication COVID-19
Phase Phase III
Title MP0420 for Inpatients With COVID-19 (An ACTIV-3/?TICO Treatment Trial)
Status Completed
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
References
1 DARPins stack up as anti-COVID-19 agents. Nat Biotechnol. 2020 Dec;38(12):1369.
2 Molecular Partners. Product Development Pipeline. 2021.